My short presentation will focus on 3 following topics: Prevalence of obesity in Vietnam and alarming increasing prevalence of obesity in recent years, especially in children
In May 2025, Illumina, Inc., and Ovation.io, Inc., announced the development of the largest commercially available clinical multiomic dataset from 25,000 patients treated with glucagon-like peptide-1 (GLP-1) receptor agonist therapies
Here is the comprehensive approach that produces the best transformations
12 Since its approval by the US Food and Drug Administration in 2021, semaglutide has been sold under the brand names Ozempic, Rybelsus, and Wegovy as an anti-diabetic and anti-obesity treatment
The majority of evidence supporting the practice of microdosing GLP-1 medications, however, comes from anecdotal evidence and reported benefits from patients and clinicians
Some patients report more frequent, looser stools, particularly after eating or during the first few weeks of treatment
